Browse the evidence

Initiating anti-obesity medications more than 12 months after bariatric surgery is associated with a significantly lower risk of adverse events compared to initiation within the first 12 months.

If you are considering weight loss medication after bariatric surgery, current evidence suggests it may be safer to wait until at least 12 months have passed since your surgery. Starting medication earlier is associated with a much higher risk of adverse events, though this may be partly due to the natural recovery period of the surgery itself rather than the drug alone.

The menopausal transition is associated with a reduction in lean or muscle mass, with postmenopausal women showing approximately 5.7% lower muscle mass compared to premenopausal women, although this correlation may be confounded by aging and measurement limitations of DXA.

If you are going through menopause, expect a potential decline in muscle mass, particularly during the perimenopausal transition. This is not necessarily inevitable or irreversible. Focus on resistance training and adequate protein intake during this window, as it is a critical period where interventions may be most effective in preventing sarcopenia.

Older women may exhibit elevated fasted muscle protein synthesis (MPS) rates compared to younger women or age-matched men, but their MPS response to anabolic stimuli like resistance exercise or protein ingestion may be blunted.

As you age, your muscles may not respond as strongly to exercise and protein as they did when you were younger. This doesn't mean exercise is useless, but it does mean you may need to be more consistent and potentially adjust your protein intake to maximize muscle protein synthesis.

Performing resistance training in the late afternoon/evening yields greater muscle hypertrophy compared to morning training in young, intermediate chronotype males.

If your goal is maximum muscle growth and you are a young adult with a normal schedule, try to schedule your weightlifting sessions for the late afternoon or early evening (e.g., 4 PM - 8 PM). This timing aligns with higher BMAL1 gene expression and body temperature, potentially optimizing muscle synthesis compared to morning sessions.

Support Vector Regression (SVR) machine learning models can accurately predict weight loss, fasting blood glucose, and HbA1c outcomes in Type 2 diabetic patients treated with Exenatide, enabling optimized nursing care and treatment decisions.

For nurses managing diabetic patients on Exenatide, using validated machine learning models (specifically SVR) can significantly improve the accuracy of predicting weight loss and glycemic control (HbA1c/Fasting Glucose). This allows for proactive adjustments to nursing care plans, dietary advice, and lifestyle interventions before complications arise, rather than reacting to poor outcomes after they occur.

Garcinia cambogia (Hydroxycitric acid/HCA) supplementation reduces visceral fat and improves fasting blood glucose and insulin sensitivity in overweight/obese individuals.

Garcinia cambogia (HCA) at 1,000 mg/day may help reduce visceral fat and improve blood sugar in overweight people, but it is not a magic bullet. It works by blocking fat synthesis and suppressing appetite.

Coleus forskohlii (Forskolin) supplementation reduces body fat, increases lean mass, and improves insulin sensitivity in overweight/obese men.

Coleus forskohlii (Forskolin) taken daily for 12 weeks may help reduce body fat and increase lean mass in overweight men, improving insulin sensitivity. It works by increasing cAMP, which stimulates fat breakdown.

Banaba leaf extract (Corosolic acid) and Resistant Maltodextrin (RMD) improve blood glucose control and insulin sensitivity through distinct mechanisms.

Banaba leaf extract and Resistant Maltodextrin (RMD) can improve blood glucose control and insulin sensitivity. Banaba works by promoting glucose uptake, while RMD delays carbohydrate absorption and increases SCFA production.

High intake of linoleic acid (LA) relative to n-3 fatty acids (EPA/DHA) promotes inflammation, thrombosis, and allergic diseases by increasing the tissue ARA/EPA ratio and producing more potent inflammatory eicosanoids (LT C4, TX A2).

To reduce inflammation and thrombotic risk, prioritize foods rich in n-3 fatty acids (EPA/DHA) and limit high-linoleic acid vegetable oils (safflower, sunflower, corn). A lower tissue ARA/EPA ratio is associated with reduced allergic, inflammatory, and thrombotic disease risk.

Carriers of the TCF7L2 rs7903146 T allele exhibit significantly attenuated weight loss and metabolic improvements compared to non-T allele (CC) carriers when following a partial meal replacement (pMR) hypocaloric diet.

If you have the TCF7L2 rs7903146 T allele, expect your weight loss to be roughly half as fast as someone with the CC genotype on a similar meal-replacement diet. Focus on metabolic health markers (blood sugar, insulin) as early wins, as these improve significantly even if the scale moves slower.

Pharmacotherapy with semaglutide (1 mg/week) and/or metformin (0.5g 3x/day) combined with lifestyle interventions produces weight loss comparable to low-carbohydrate diets and balanced diets at 3 months, despite potentially faster initial results.

Pharmacotherapy (semaglutide/metformin) combined with lifestyle changes is an effective weight loss strategy that yields similar results to dietary changes after 3 months. It is not just for 'severe' cases but can be a valid option for those struggling with diet alone.

Animal-based proteins provide a modest but statistically significant advantage in stimulating muscle protein synthesis (MPS) compared to plant-based proteins, primarily driven by higher leucine content and bioavailability.

If you are over 65, prioritize animal proteins (whey, milk, eggs) or ensure your plant protein is high-leucine (soy, pea blends) to maximize muscle growth. For younger adults, plant and animal proteins appear functionally equivalent for MPS when doses are matched.

The MPS advantage of animal proteins over plant proteins is significantly more pronounced in older adults (65+) than in younger adults, likely due to the 'leucine threshold'.

If you are over 65, ensure your plant proteins are high-leucine (e.g., soy, pea) or consider animal proteins to overcome age-related anabolic resistance. Younger adults can likely use either source effectively.

Individuals with high obesity genetic risk scores (GRS) experience greater initial weight loss during the first 6 months of behavioral interventions but are significantly more susceptible to weight regain during the subsequent 6 months compared to those with low GRS.

If you have a strong family history of obesity, expect to lose weight quickly when you start a diet, but be vigilant about maintenance. Your body may fight back harder to regain weight after the initial loss. Focus heavily on the strategies that help you maintain weight loss after the first 6 months, as this is where your genetic risk profile shows a tendency for regain.

Chronic administration of the GLP-1/GIP dual agonist I-M-150847 significantly improves glycemic control and reduces body weight and adiposity in diet-induced obese rodents compared to the GLP-1 monoagonist exendin-4.

This preclinical study suggests that a novel dual GLP-1/GIP agonist (I-M-150847) may provide better blood sugar control and weight loss than current GLP-1-only drugs in obese individuals with type 2 diabetes. While promising in mice, human clinical data is required before this can be recommended for clinical use.

Carbohydrate-restricted nutrition therapy (CRNT) supported by continuous remote care enables the deprescription of GLP-1 receptor agonists in people with type 2 diabetes without regression of glycemic control or body weight loss.

If you are on a GLP-1 drug (like Ozempic or Wegovy) for Type 2 Diabetes or weight, you do not necessarily have to take it forever. This study suggests that if you adopt a medically-supervised ketogenic diet (low carb, high healthy fat) and monitor your blood ketones, you may be able to stop the drug while keeping your weight and blood sugar stable. The key is that the diet reduces hunger hormones, doing the job the drug was doing, allowing you to step off the medication without regaining weight.

Combination pharmacotherapy for obesity is significantly more effective than monotherapy.

If one weight loss medication isn't working well, ask your doctor about combination therapies. They combine two drugs to target different pathways, often resulting in greater weight loss than a single drug.

Patients with Type 2 Diabetes Mellitus (T2DM) experience greater cardiovascular benefits and fewer adverse events from Tirzepatide compared to patients with obesity alone.

If you have both T2DM and obesity, or just T2DM, you may get more cardiovascular benefits and fewer side effects from Tirzepatide than if you have obesity alone. This suggests that your specific health condition plays a role in how well the medication works for you. Discuss your specific health profile with your doctor to understand what to expect.

GLP-1 receptor agonist therapy initiated at least one year after bariatric surgery produces additional significant weight loss with a favorable safety profile.

If you had bariatric surgery and are struggling with weight regain, GLP-1 medications (like semaglutide or dulaglutide) can help you lose more weight safely. Start with a low dose and work up slowly to minimize stomach issues. Combining the medication with a structured lifestyle program (like the VA's MOVE!) yields the best results.

GLP-1 receptor agonists (GLP-1RAs) improve reproductive outcomes in obese women with PCOS or unexplained infertility by reducing body weight, improving insulin sensitivity, and modulating endometrial immune balance (increasing Treg cells, decreasing pro-inflammatory cytokines, and restoring Th17/Treg balance).

For women with obesity and fertility issues (like PCOS), GLP-1 medications can help restore ovulation and improve the uterine environment by lowering inflammation. However, these drugs must be stopped before you conceive because they can harm the developing embryo. The goal is to use them during the preconception phase to fix metabolic and immune imbalances, then switch to pregnancy-safe management once pregnant.

MBS leads to marked improvements in sexual function for both men and women, including increased libido, erectile function, and hormonal normalization, typically within the first 12 months.

Expect significant improvements in sexual function and hormonal health within the first year after surgery. These changes are driven by weight loss and hormonal recalibration. Address any performance anxiety through counseling to maximize benefits.

GLP-1 receptor agonists (e.g., semaglutide) induce significant weight loss through hormonal mechanisms but carry a high risk of psychological dependency and rebound weight gain upon discontinuation, necessitating their use as temporary adjuncts to lifestyle interventions rather than standalone long-term solutions.

If you are using GLP-1 drugs, treat them as a temporary bridge to build sustainable habits, not a permanent solution. Prioritize resistance training and protein intake to protect muscle mass, as rapid weight loss without exercise increases frailty risk. Plan for discontinuation early by integrating behavioral therapy and dietary changes to prevent rebound weight gain and dependency.

Tirzepatide, a dual GLP-1/GIP receptor agonist, demonstrates significant efficacy in reducing body weight (over 20% in some cases) and improving glycemic control in patients with type 2 diabetes and obesity, suggesting therapeutic potential for women with Polycystic Ovary Syndrome (PCOS) who have comorbid obesity and insulin resistance.

For women with PCOS and obesity, tirzepatide offers a promising pharmacological tool to address both metabolic and reproductive symptoms. While not yet standard care for PCOS specifically, its ability to induce significant weight loss (>20%) and improve insulin sensitivity suggests it may help restore ovulation and reduce androgen levels. Treatment involves weekly subcutaneous injections starting at 2.5mg and titrating up to 15mg, ideally combined with lifestyle changes. Patients should be aware of potential GI side effects, though the drug's design aims to mitigate them.

GLP-1 agonists (semaglutide, tirzepatide) produce significant weight loss (15-21%) but are associated with isolated reports of depression and suicidal ideation, though causal links remain unproven.

GLP-1 medications like semaglutide and tirzepatide are highly effective for weight loss (15-21%), but require careful psychological monitoring. While serious mental health side effects are reported, they are isolated and not causally proven. You should undergo regular mental health check-ins alongside your medical treatment to ensure safety.